Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer

Biomedicines - Switzerland
doi 10.3390/biomedicines8020022
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

New and Emerging HDAC Inhibitors for Cancer Treatment

Journal of Clinical Investigation
Medicine
2014English

Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer

Current Pharmaceutical Design
Drug DiscoveryPharmacology
2016English

PARP Inhibitors and Stratified Treatment of Prostate Cancer

Expert Review of Anticancer Therapy
OncologyPharmacology
2016English

HDAC Inhibitors Show Benefits in Breast Cancer

Cancer Discovery
Oncology
2011English

Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic

2013English

Identification of HDAC Inhibitors Using a Cell-Based HDAC I/Ii Assay

Journal of Biomolecular Screening
Molecular MedicinePharmacologyBiochemistryAnalytical ChemistryBiotechnologyDrug Discovery
2016English

Stabilized Peptide HDAC Inhibitors Derived From HDAC1 Substrate H3K56 for the Treatment of Cancer Stem-Like Cells in Vivo

Cancer Research
Cancer ResearchOncology
2019English

Differential Response of Cancer Cells to HDAC Inhibitors Trichostatin a and Depsipeptide

British Journal of Cancer
Cancer ResearchOncology
2011English

Improving the Content Of, and Patient Access To, Prostate Cancer Treatment Decision Information

Californian Journal of Health Promotion
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy